155 related articles for article (PubMed ID: 23793813)
1. Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain.
Balañá C; Vaz MA; Lopez D; de la Peñas R; García-Bueno JM; Molina-Garrido MJ; Sepúlveda JM; Cano JM; Bugés C; Sanz SM; Arranz JL; Perez-Segura P; Rodriguez A; Martin JM; Benavides M; Gil M
Clin Transl Oncol; 2014 Mar; 16(3):273-9. PubMed ID: 23793813
[TBL] [Abstract][Full Text] [Related]
2. Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma.
Hsieh SY; Chan DT; Kam MK; Loong HH; Tsang WK; Poon DM; Ng SC; Poon WS
Hong Kong Med J; 2017 Dec; 23(6):594-8. PubMed ID: 28798282
[TBL] [Abstract][Full Text] [Related]
3. Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma.
Darlix A; Baumann C; Lorgis V; Ghiringhelli F; Blonski M; Chauffert B; Zouaoui S; Pinelli C; Rech F; Beauchesne P; Taillandier L
Anticancer Res; 2013 Aug; 33(8):3467-74. PubMed ID: 23898121
[TBL] [Abstract][Full Text] [Related]
4. [Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma].
Malkoun N; Fotso MJ; Cartier L; Forest F; Auberdiac P; Chargari C; Thorin J; Pacaut C; Peoc'h M; Nuti C; Schmitt T; Magné N
Cancer Radiother; 2011 Jun; 15(3):202-7. PubMed ID: 21450506
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States.
Messali A; Hay JW; Villacorta R
Neuro Oncol; 2013 Nov; 15(11):1532-42. PubMed ID: 23935155
[TBL] [Abstract][Full Text] [Related]
6. Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme.
Roldán Urgoiti GB; Singh AD; Easaw JC
J Neurooncol; 2012 May; 108(1):173-7. PubMed ID: 22382781
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide (Temodar).
Wesolowski JR; Rajdev P; Mukherji SK
AJNR Am J Neuroradiol; 2010 Sep; 31(8):1383-4. PubMed ID: 20538821
[TBL] [Abstract][Full Text] [Related]
10. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A
Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M
Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Stupp R; Mason WP; van den Bent MJ; Weller M; Fisher B; Taphoorn MJ; Belanger K; Brandes AA; Marosi C; Bogdahn U; Curschmann J; Janzer RC; Ludwin SK; Gorlia T; Allgeier A; Lacombe D; Cairncross JG; Eisenhauer E; Mirimanoff RO; ;
N Engl J Med; 2005 Mar; 352(10):987-96. PubMed ID: 15758009
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany.
Waschke A; Arefian H; Walter J; Hartmann M; Maschmann J; Kalff R
J Neurooncol; 2018 Jun; 138(2):359-367. PubMed ID: 29468446
[TBL] [Abstract][Full Text] [Related]
14. A small proportion of glioblastoma patients are probably eligible for concomitant/adjuvant temozolomide.
O'Toole L; Khanduri S; Gerrard GE
Clin Oncol (R Coll Radiol); 2007 May; 19(4):269. PubMed ID: 17433972
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.
Lamers LM; Stupp R; van den Bent MJ; Al MJ; Gorlia T; Wasserfallen JB; Mittmann N; Jin Seung S; Crott R; Uyl-de Groot CA;
Cancer; 2008 Mar; 112(6):1337-44. PubMed ID: 18213621
[TBL] [Abstract][Full Text] [Related]
16. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
17. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S
J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182
[TBL] [Abstract][Full Text] [Related]
18. Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study.
Fabbro-Peray P; Zouaoui S; Darlix A; Fabbro M; Pallud J; Rigau V; Mathieu-Daude H; Bessaoud F; Bauchet F; Riondel A; Sorbets E; Charissoux M; Amelot A; Mandonnet E; Figarella-Branger D; Duffau H; Tretarre B; Taillandier L; Bauchet L
J Neurooncol; 2019 Mar; 142(1):91-101. PubMed ID: 30523606
[TBL] [Abstract][Full Text] [Related]
19. Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis.
Roussakow SV
BMJ Open; 2017 Nov; 7(11):e017387. PubMed ID: 29102988
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
Clarke JL; Iwamoto FM; Sul J; Panageas K; Lassman AB; DeAngelis LM; Hormigo A; Nolan CP; Gavrilovic I; Karimi S; Abrey LE
J Clin Oncol; 2009 Aug; 27(23):3861-7. PubMed ID: 19506159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
